OncoC4, Inc.

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
CTLA-4Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 1
PD-1 x CTLA-4Combination
Non-Small Cell Lung Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
GotistobartPhase 1/2Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2026-11-30 · NCT05682443 · CT.gov ↗
What to watch
December 2026 (1)
GotistobartPhase 1/2Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma …
Est. primary completion 2026-12-31 · NCT04140526 · CT.gov ↗
What to watch
2027 (1)
August 2027 (1)
GotistobartPhase 3Non Small Cell Lung Cancer
Est. primary completion 2027-08-31 · NCT05671510 · CT.gov ↗
What to watch
2036 (1)
July 2036 (1)
GotistobartPhase 3Advanced Solid Tumor
Est. primary completion 2036-07-01 · NCT07659379 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 December 2025PresentationGotistobartPRESERVE-003 Stage 1 overall survival data presented
BioNTech SE and OncoC4, Inc. · Source ↗

Financial reports

No financial reports recorded.